Tissue Inhibitor of Matrix-Metalloprotease–1 Predicts Risk of Hepatic Fibrosis in Human Schistosoma japonicum Infection

Fabre, Valeria; Wu, Haiwei; Pond-Tor, Sunthorn; Coutinho, Hannah M.; Acosta, Luz P.; Jiz, Mario; Olveda, Remigio M.; Cheng, Ling; White, Eric S.; Jarilla, Blanca; McGarvey, Stephen T.; Friedman, Jennifer F.; Kurtis, Jonathan D.

doi:10.1093/infdis/jiq099

Cited by 32 publications

(34 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As shown previously [28], the assay demonstrates <10% median inter-analyte interference, and the median intra-assay coefficient of variation, as assessed by 28 replicate serum controls, was 18%. The lower limit of detection was 7.93 pg·mL −1 for MMP-7, 2.63 pg·mL −1 for FasL, 25.53 pg·mL −1 for OPN, and 76.0 ng·mL −1 for PICP.…”

Section: Methodssupporting

confidence: 76%

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

Bauer

White

Bernard³

et al. 2017

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with poor prognosis, which is characterised by destruction of normal lung architecture and excessive deposition of lung extracellular matrix. The heterogeneity of disease progression in patients with IPF poses significant obstacles to patient care and prevents efficient development of novel therapeutic interventions. Blood biomarkers, reflecting pathobiological processes in the lung, could provide objective evidence of the underlying disease.Longitudinally collected serum samples from the Bosentan Use in Interstitial Lung Disease (BUILD)-3 trial were used to measure four biomarkers (metalloproteinase-7 (MMP-7), Fas death receptor ligand, osteopontin and procollagen type I C-peptide), to assess their potential prognostic capabilities and to follow changes during disease progression in patients with IPF.In baseline BUILD-3 samples, only MMP-7 showed clearly elevated protein levels compared with samples from healthy controls, and further investigations demonstrated that MMP-7 levels also increased over time. Baseline levels of MMP-7 were able to predict patients who had higher risk of worsening and, notably, baseline levels of MMP-7 could predict changes in FVC as early as month 4.MMP-7 shows potential to be a reliable predictor of lung function decline and disease progression.

show abstract

Section: Methodssupporting

confidence: 76%

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

Bauer

White

Bernard³

et al. 2017

ERJ Open Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…This highlights the importance of identifying biomarkers for fibrosis risk because fibrosis can occur despite effective treatment. 99 …”

Section: Matrix Metalloproteinases and Inhibitorsmentioning

confidence: 99%

The chronic enteropathogenic disease schistosomiasis

Olveda¹,

Olveda

McManus

et al. 2014

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Schistosomiasis is a chronic enteropathogenic disease caused by blood flukes of the genus Schistosoma. The disease afflicts approximately 240 million individuals globally, causing approximately 70 million disability-adjusted life years lost. Chronic infections with morbidity and mortality occur as a result of granuloma formation in the intestine, liver, or in the case of Schistosoma haematobium, the bladder. Various methods are utilized to diagnose and evaluate liver fibrosis due to schistosomiasis. Liver biopsy is still considered the gold standard, but it is invasive. Diagnostic imaging has proven to be an invaluable method in assessing hepatic morbidity in the hospital setting, but has practical limitations in the field. The potential of non-invasive biological markers, serum antibodies, cytokines, and circulating host microRNAs to diagnose hepatic fibrosis is presently undergoing evaluation. This review provides an update on the recent advances made with respect to gastrointestinal disease associated with chronic schistosomiasis.

show abstract

“…All of these markers were evaluated in cord blood from pregnancies with and without maternal schistosome infection. Each of the 10 schistosome-associated profibrotic proteins identified in this report has been associated with fibrosis in children and nonpregnant adults with schistosomiasis (9,(25)(26)(27). However, the elevation of these markers in neonates is remarkable, because there is no evidence for vertical transmission of schistosomiasis japonica in humans, despite its occurrence in other mammals with very different placental morphology (28).…”

Section: Discussionmentioning

confidence: 68%

“…We developed a multiplex, bead-based assay (FibroPlex version 2) to measure 36 different predictors, mediators, and outcomes of fibrosis. This assay builds upon our original assay (FibroPlex), which contained TGF-␤1, TIMP-1, macrophage inflammatory protein 1␣ (MIP-1␣), IL-13R␣2, bone morphogenic protein 7 (BMP-7), CTGF, matrix metalloproteinase 1 (MMP-1), and IL-13 (9). We expanded this assay to include additional key predictors or regulators of hepatic and pulmonary fibrosis.…”

Section: Methodsmentioning

confidence: 99%

“…A number of other Th2 cytokines, profibrotic growth factors, and mediators of extracellular matrix (ECM) accumulation contribute to the development of fibrosis, including transforming growth factor ␤1 (TGF-␤1), thrombin, monocyte chemotactic protein 1 (MCP-1), and connective tissue growth factor (CTGF) (8). We have previously shown that PBMC production of tissue inhibitor of metalloproteinases 1 (TIMP-1) in response to SEA predicts severe fibrosis in patients for which initial schistosome infection has been resolved (9), suggesting that these molecules are not just a result of fibrosis but may serve as biomarkers of risk of future fibrosis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Maternal Infection with Schistosoma japonicum Induces a Profibrotic Response in Neonates

et al. 2014

Self Cite

View full text Add to dashboard Cite

fThe global burden of schistosomiasis is significant, with fibrosis a major associated morbidity and the primary cause of mortality. We have previously shown that schistosomiasis during pregnancy upregulates proinflammatory cytokines in the cord blood. In this study, we extend these findings to include a large panel of fibrosis-associated markers. We developed a multiplex beadbased assay to measure the levels of 35 proteins associated with fibrosis. Cord blood from 109 neonates born to mothers residing in an area of Schistosoma japonicum endemicity was assessed for these molecules. Ten mediators were elevated in the cord blood from schistosome-infected pregnancies, including insulin-like growth factor 1 (IGF-1), tumor growth factor ␤1 (TGF-␤1), connective tissue growth factor (CTGF), procollagen I carboxy-terminal propeptide (PICP), amino-telopeptide of type 1 collagen (ICTP), collagen VI, desmosine, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), and TIMP-4. Many of these were also positively correlated with preterm birth (PICP, ICTP, MMP-2, TGF-␤1, desmosine, CTGF, TIMP-1). In addition, birth weight was 168 g lower for infants with detectable levels of CTGF than for those with CTGF levels below the level of detection. Maternal schistosomiasis results in upregulation of fibrosis-associated proteins in the cord blood of the neonate, a subset of which are also associated with adverse birth outcomes. As the first report of fibrosis-associated molecules altered in the newborn of infected mothers, this study has broad implications for the health of the fetus, stretching from gestation to adulthood.

show abstract

Tissue Inhibitor of Matrix-Metalloprotease–1 Predicts Risk of Hepatic Fibrosis in Human Schistosoma japonicum Infection

Cited by 32 publications

References 46 publications

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

The chronic enteropathogenic disease schistosomiasis

Maternal Infection with Schistosoma japonicum Induces a Profibrotic Response in Neonates

Contact Info

Product

Resources

About